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Plasmodium gametocytes develop from their asexual progenitors and are the only malaria 57 
parasite life-stage infective to mosquitoes. In preparation for their development in the 58 
mosquito, gametocytes cease to express many proteins involved in the parasites cycle of 59 
asexual replication, and upregulate others that are involved in sexual development [1,2]. 60 
Some of these have essential roles in mosquito-stage development [3,4], which culminates 61 
in the insect becoming infectious to humans.  62 
In surveys where mosquitoes were fed directly on the skin or on a blood sample, it was 63 
noted that some gametocytaemic individuals including those with high gametocyte densities 64 
were not infectious [5,6]. This may be associated with naturally acquired antibodies that 65 
interfere with parasite development within mosquitoes to reduce or prevent mosquito 66 
infection [7,8]. The role of antibodies in determining transmission efficiency can be tested in 67 
mosquito-feeding assays, in which purified antibodies are added to a mosquito blood meal 68 
that contains gametocytes [9,10]. Evidence for naturally acquired transmission-reducing 69 
activity (TRA) is provided if test antibodies in endemic serum cause a reduction in the 70 
number of developing Plasmodium oocysts relative to mosquitoes fed the same infectious 71 
blood meal without test antibodies. TRA can be experimentally induced after immunisation of 72 
animals with inactivated Plasmodium gametocytes or gametes [8,11]. The gametocyte and 73 
gamete proteins P48/45 and P230 have been identified as targets of transmission-blocking 74 
monoclonal antibodies (mAb), which act by inhibiting the protein’s role in gamete fertilisation 75 
in the mosquito gut [3,4,12]. Monoclonal antibodies specific to the zygote and ookinete 76 
proteins P25 and P28 were also shown to block transmission, by inhibiting ookinete invasion 77 
of the midgut epithelium13. All four have been produced as recombinant proteins that can 78 
induce antibody-mediated TRA in animal models [13–15]. 79 
Because P25 and P28 mRNA is translationally repressed until zygote formation [16], 80 
antibodies specific to these proteins appear absent in endemic populations [17,18]. In 81 
contrast, responses to P48/ 45 and P230 are commonly observed in naturally infected 82 
individuals [10,19,20]. The presence of antibodies to Plasmodium falciparum Pfs48/45 and 83 
Pfs230 in endemic sera has been associated with TRA in several, but not all sero-84 
epidemiological surveys [10,21–28]. Importantly, many individuals with functional TRA do not 85 
have measurable antibodies against these two proteins [10,23,25,28–31]. Despite these 86 
observations, there has been no attempt to demonstrate the contribution of naturally 87 
acquired α-Pfs48/45 and α-Pfs230 antibodies to transmission inhibition, and little 88 
investigation of alternative targets of natural TRA. The gametocyte proteome has now been 89 
described in detail [32,33]. Utilising the protein microarray platform, genome scale data sets 90 
have been combined with functional and immunological data to provide valuable insight into 91 
mechanisms and markers of malaria humoral immunity [34,35]. 92 
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Here, we aim to investigate the immune signature of naturally occurring antibody-mediated 93 
TRA, to expand and prioritise antigenic targets for functional characterisation as biomarkers, 94 
or transmission-blocking vaccine candidates. To this purpose, we utilise a protein microarray 95 
comprising an inclusive selection of proteins expressed during gametocyte development. We 96 
assess antibody responses to these proteins and to correctly folded Pfs48/4536 and 97 
Pfs23015 in 648 malaria-exposed individuals from Burkina Faso, the Gambia, Cameroon, 98 
and from migrants from the Netherlands. Using purified total IgG, we assess the functional 99 
TRA of antibodies from the same individuals by determining their effect on mosquito 100 
infection density in standard membrane feeding assays (SMFA) with cultured P. falciparum 101 
gametocytes and Anopheles stephensi mosquitoes. Our analysis reveals significant 102 
associations between high-level TRA and responses to Pfs48/45, Pfs230 and 43 novel 103 
gametocyte proteins. For a subset of 366 gametocyte-positive donors who had provided 104 
blood samples to Anopheles gambiae s.s. or An. coluzzii mosquitoes in field-based 105 
membrane-feeding assays, we determine the association of these antibody responses with 106 
mosquito infection rates during natural infections. For Pfs48/45 and Pfs230, we provide 107 
functional data that demonstrate their role in natural TRA. For one of the newly identified 108 
proteins (PfGEST), we provide experimental data that does not support its functional role in 109 
natural TRA. 110 
 111 
Results 112 
Antibody responses to gametocyte antigens. Plasma was collected in epidemiological 113 
studies in Burkina Faso [37–41], Cameroon [42,43] and the Gambia [24,44–48], as well as 114 
from Dutch migrants who had lived for several years in malaria-endemic areas and reported 115 
repeated malaria episodes (Table 1). Individuals from malaria-endemic areas were all 116 
asymptomatic when sampled, and were either recruited randomly from the community (n= 117 
42), or based on the observation of malaria parasites (n = 273) or specifically gametocytes 118 
(n = 276) in blood smears. For a selection of individuals from malaria-endemic areas (n = 119 
498), infectivity to mosquitoes at the moment of sample collection was determined by 120 
offering a venous blood sample to Anopheles gambiae s.s. or An. coluzzii in a direct 121 
membrane-feeding assay (DMFA) (Table 1). Dutch migrants had no DMFA performed and 122 
had either recently returned from extended periods in endemic areas (within 6 months after 123 
return; n = 8) or had returned more than a year before sampling (n = 49). Those who had 124 
returned more than a year before sampling had lived in areas with endemic P. falciparum 125 
transmission for longer than 15 years, and reported between 2 and >80 clinical malaria 126 
episodes during that time.  127 
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Antibody responses to Pfs48/45 (Pfs48/45-10C [36]) and Pfs230 (230CMB [15]) were 128 
determined by enzyme-linked immunosorbent assay (ELISA) using recombinant, correctly 129 
folded proteins. A protein microarray was constructed to assess responses to other 130 
gametocyte antigens. This array included a total of 315 proteins (Supplementary Data 1) that 131 
were broken up into 528 overlapping fragments <1000 amino acids in length (overlaps of 17 132 
amino acids) for protein expression in an Escherichia coli based in vitro transcription–133 
translation (IVTT) system [49,50]. Antigens on the array included proteins previously 134 
implicated as eliciting TRA after immunisation, proteins involved in early gametocyte 135 
development as possible markers of gametocyte exposure1, markers of asexual parasite 136 
exposure [51] and proteins expressed in gametocytes based on recent proteomic analysis 137 
[52]. To ensure that the array included most potential antibody targets involved in TRA, we 138 
preferentially included proteins that had transmembrane domains, signal peptides or GPI 139 
anchors. Specificity of proteins to gametocytes was not a prerequisite for inclusion on the 140 
array, however 228/315 proteins had consensus evidence for enrichment in gametocytes 141 
based on a recent integration analysis of 11 available proteomics data sets [53] 142 
(Supplementary Data 1). Among donors from malaria-endemic regions, the prevalence and 143 
magnitude of antibody responses to Pfs48/45 and Pfs230 increased with age (Fig. 1a–d). In 144 
contrast, the overall breadth (linear regression (LinR): p < 0.001) and magnitude (analysis of 145 
variance (ANOVA): p = 0.013) of response to antigens on the microarray decreased with age 146 
(Fig. 1e, f). The same associations were observed when analyses were restricted to donors 147 
from Burkina Faso (n = 225), the site with the widest age range of donors (Supplementary 148 
Fig. 1). 149 
Antibody responses and transmission-reducing activity (TRA). To assess functional 150 
TRA, IgG was purified from the sera of all 648 individuals and provided to Anopheles 151 
stephensi mosquitoes together with a blood meal containing cultured NF54 or transgenic 152 
NF54HT-GFP-Luc gametocytes in standard membrane feeding assays (SMFA) [9,54]. If the 153 
donor IgG caused ≥80% reduction in oocyst formation relative to control mosquitoes (TRA 154 
≥80%), the SMFA was repeated with separate gametocyte culture material. In total, 3.3% 155 
(22/648) of the antibody samples caused replicable TRA of ≥ 90% (Table 1). On a 156 
continuous scale, TRA decreased with age, but was not significantly associated with 157 
gametocyte density at the point of sampling (LinR: p = 0.269) (Supplementary Fig. 2). 158 
Because previous gametocyte exposure is associated with TRA28, comparisons between 159 
sub-groups were nevertheless adjusted for gametocyte density. Though intermediate TRA 160 
may be relevant for transmission there are uncertainties about its reliable measurement in 161 
the SMFA [55,56]. TRA was therefore dichotomised into ≥90% (high-level TRA) and <10% 162 
TRA (no TRA) before assessing associations with antibody responses. The group without 163 
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evidence for TRA was refined by excluding individuals without microscopically detectable 164 
gametocyte densities at the time of sampling, resulting in 22 individuals with high-level TRA 165 
activity and 254 individuals who were exposed to gametocytes (and thus likely to respond to 166 
gametocyte antigens) but showed no evidence for TRA. Using these two categories, high-167 
level TRA was significantly more likely in individuals seropositive for α-Pfs230 (odds-ratio 168 
(OR) from logistic regression (LogR) 7.9 (95% confidence interval (CI): 2.8–22.8), p < 0.001), 169 
α-Pfs48/45 (OR 4.4 (95% CI: 1.5–12.9), p = 0.007) or either antigen (OR 5.90 (95% CI: 2.1–170 
16.7), p = 0.001) (Supplementary Table 1, Supplementary Data 2). Antibody density was 171 
also higher for Pfs230 (LinR: p < 0.001) and Pfs48/45 (p < 0.001) in individuals exhibiting 172 
high-level TRA (Fig. 2a, b; Supplementary Data 2).  173 
In addition to Pfs230 and Pfs48/45, the average magnitude of response to each microarray 174 
target was also higher in individuals with high-level TRA (students t-test: p = 0.012) (Fig. 2d), 175 
whilst the breadth of response by each individual was not statistically significantly different 176 
between individuals with high-level TRA compared to those with no evidence of TRA (LinR: 177 
p = 0.89) (Fig. 2c). Sixty microarray proteins had statistically significantly higher antibody 178 
magnitude in individuals with high-level TRA, after p-values had been adjusted to control the 179 
false discovery rate (FDR) (Fig. 2e) [57]. The inverse, higher responses in individuals with no 180 
TRA, was not observed (Supplementary Data 3). Logistic regression models with FDR 181 
controlled p-values showed that antibody prevalence to 27 microarray targets was 182 
significantly associated with high-level TRA, 25 of which were also significantly more 183 
reactive in the analysis of signal intensity. Because large proteins were fragmented on the 184 
array, the combined list of 62 novel microarray targets with TRA associated antibody 185 
responses in either the linear (response intensity) or logistic (response prevalence) analysis 186 
represented fragments of 43 unique proteins (Supplementary Data 2). 15 of the 43 proteins 187 
with TRA-associated responses are conserved unknown proteins. Two are known 188 
gametocyte/gamete proteins with putative roles in gamete egress; PF3D7_1038400 189 
(gametocyte-specific protein, Pf11-1) and PF3D7_1449000 (gamete surface and sporozoite 190 
traversal protein/GEST).  191 
TRA-associated responses on the array showed only partial overlap with Pfs48/45 and 192 
Pfs230 responses. Individuals with high-level TRA who were seronegative for both α-Pfs230 193 
and α-Pfs48/45 (n = 10/22), had antibody responses to significantly more TRA-associated 194 
microarray targets (median breadth 11 (out of 62) (interquartile range (IQR) 3–26)) than 195 
gametocyte-positive individuals without TRA (n = 211; median breadth 4 (out of 62) (IQR 2–196 
9), LinR: p = 0.018). Responses to some TRA biomarkers were highly prevalent in 197 
individuals with high-level TRA who lacked significant responses to Pfs45/45 and Pfs230 198 
(e.g. Pf11-1 (PF3D7_103840) = 70% (n/N = 7/10); LSA3 (PF3D7_0220000) = 80% (n/N = 199 
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8/10)). Responses to one target protein mapping to PF3D7_1103800 (CCR4-NOT) were 200 
present in 60% (n/N = 6/10) of high-level TRA α-Pfs48/45 and α-Pfs230 seronegatives, 201 
whereas seroprevalence for this target in individuals with no TRA was 10.3% (n/N = 26/254) 202 
(Supplementary Data 4).  203 
Interestingly, 10 of the 43 proteins with TRA-associated antibody responses are putatively 204 
exported during early gametogenesis1. Though the majority of these proteins are enriched in 205 
asexual parasites, their association with TRA may reflect previous observations that TR 206 
immunity is induced and wanes rapidly after gametocyte exposure [26,27]. Responses to 207 
putative markers of asexual parasite exposure (PF3D7_1036000 (Merozoite surface protein 208 
11 (MSP11)), PF3D7_0711700 (erythrocyte membrane protein 1, PfEMP1 (VAR)), 209 
PF3D7_0731600 (acyl-CoA synthetase (ACS5)), and PF3D7_0423700 (early-transcribed 210 
membrane protein 4 (ETRAMP4)) [51] were not associated with TRA, either in terms of 211 
response intensity (Bayes empirical t-test: FDR-adjusted p = 0.34–0.99) or seroprevalence 212 
(LogR: FDR-adjusted p = 1). 213 
 214 
TRA and mosquito infection rate in natural infections. Next, we determined whether the 215 
immune profile associated with TRA in the SMFA was also associated with mosquito 216 
infection rates observed in direct membrane-feeding experiments. Data on the infectivity of 217 
donor blood samples to mosquitoes at the time of plasma donation was available for 494 218 
individuals for whom gametocyte status had been assessed by microscopy and TRA 219 
assessed in the SMFA. Of the 128 individuals without patent gametocytaemia, 18 (14.1%) 220 
were infective to mosquitoes in the DMFA. Of the 366 gametocyte-positive individuals, 203 221 
(55.5%) infected at least one mosquito, with a median mosquito infection rate of 20% (IQR 222 
7.7–42.5%). There was good agreement between transmission outcomes in the SMFA using 223 
cultured gametocytes and An. stephensi mosquitoes, and the field-based DMFA using 224 
gametocytes in infected individuals and An. gambiae s.s. or An. coluzzii mosquitoes; 225 
Individuals with high-level TRA in the SMFA were significantly less likely to infect any 226 
mosquitoes in the DMFA (LogR: OR 0.23 (95% CI: 0.06–0.79), p = 0.020), and more likely to 227 
do so at a reduced rate (OR 0.10 (95% CI: 0.2–0.61), p = 0.012). The likelihood of 228 
gametocyte-positive individuals infecting any mosquitoes in the DMFA was significantly 229 
lower if seropositive for Pfs230 (LogR: OR 0.42 (95% CI: 0.22–0.78), p = 0.006), Pfs48/45 230 
(OR 0.30 (95% CI: 0.16–0.59), p < 0.001), or either or both antigens (OR 0.33 (95% CI: 231 
0.19–0.58), p < 0.001) (Fig. 3a). The proportion of mosquitoes that became infected after 232 
feeding was also significantly lower for individuals seropositive for Pfs230 (LogR: OR 0.36 233 
(95% CI: 0.14–0.88), p < 0.027), Pfs48/45 (OR 0.14 (95% CI: 0.05–0.40), p < 0.001) or 234 
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either or both antigens (OR 0.25 (95% CI: 0.11–0.55), p = 0.001) (Fig. 3b). The proportion of 235 
mosquitoes that became infected decreased with increasing Pfs230 antibody density (LogR: 236 
OR for an increase of 0.1 normalised optical density 0.59 (95% CI: 0.40–0.86), p = 0.007) 237 
and Pfs48/45 antibody density (OR 0.43 (95% CI:0.28–0.66), p < 0.001).  238 
Mosquito infection prevalence was lower in gametocyte positive individuals with antibodies 239 
recognising more of the 62 novel protein microarray targets with TRA-associated antibody 240 
responses (Supplementary Fig. 3). Individuals responding to ≥14/62 microarray proteins (14 241 
being the 75th percentile of breadth of response to these targets) were significantly less 242 
likely to infect mosquitoes (LogR: OR 0.31 (95% CI: 0.18–0.51), p < 0.001), and more likely 243 
to do so at a reduced rate (OR 0.21 (95% CI: 0.09–0.45). p < 0.001) (Fig. 3a, b). After 244 
excluding Pfs48/45 or Pfs230 seropositive individuals, infectiousness and infection rate 245 
remained significantly lower in individuals responding to ≥14 of the 62 TRA-associated 246 
microarray proteins (infectiousness: LogR, OR 0.29 (95% CI: 0.16–0.53), p < 0.001, infection 247 
rate: OR 0.23 (95% CI: 0.10–0.52), p < 0.001). 248 
 249 
Functional involvement of antibodies in TRA. To demonstrate whether naturally acquired 250 
antibodies to Pfs230 or Pfs48/45 were causally associated with TRA, we affinity-purified 251 
antibodies specific to key transmission-blocking epitopes of these proteins and assessed 252 
their activity in the SMFA (Table 2). These experiments were performed for 6 donors whose 253 
IgG showed high-level TRA and for whom high volumes of plasma (≥1 mL) were available; 254 
3 of these donors had ≥10 mL plasma available, allowing additional testing after 9-fold 255 
antibody concentration of IgG. The flow-through of affinity purification experiments, depleted 256 
of α-Pfs230 and α-Pfs48/45 antibodies, was also tested in the SMFA to quantify TRA of 257 
antibodies to other target antigens. Concentrated back to the original plasma volume, α-258 
Pfs48/45 antibodies of one donor independently inhibited transmission (TRA 91.5% (95% CI: 259 
86.4–94.7)), whereas α-Pfs230 antibodies of a different donor had low but statistically 260 
significant TRA (TRA 41.1% (95% CI: 15.5–60.4)). When antibodies were concentrated to 261 
nine times their physiological concentration, α-Pfs48/45 antibodies from one additional 262 
individual, and α-Pfs230 antibodies from two additional individuals significantly reduced 263 
transmission to mosquitoes (Pfs48/45: TRA 81.3%, (95% CI: 70.9–88.0), Pfs230: TRA 94.8% 264 
(95% CI: 90.2–97.3) & 99.3% (95% 98.6–99.6), Table 2). For all individuals the α-Pfs48/45 265 
and α-Pfs230-depleted IgG (containing no antibodies against Pfs48-45 epitopes 1–3, or 266 
Pfs230 epitope C, confirmed by ELISA) inhibited transmission to mosquitoes (Table 2). This 267 
activity was complement-independent.  268 
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To determine the presence of naturally acquired antibodies binding to unknown gamete 269 
surface antigens, we performed surface immuno-fluorescence assays (SIFA) using gametes 270 
of a Pfs48/45 knockout (KO) parasite [3] that does not produce surface retained Pfs23012. 271 
Pfs48/45- and Pfs230-specific antibodies confirmed the absence of these proteins on 272 
Pfs48/45 KO gamete surfaces (Fig. 4). The immuno-fluorescence of gamete surfaces 273 
observed using total IgG and IgG depleted of α-Pfs48/45 and α- Pfs230 antibodies from 274 
naturally exposed individuals therefore reflects recognition of unknown antigens on the 275 
gamete surface (Fig. 4; Supplementary Fig. 5A).  276 
Antibody responses to a number of the 43 novel proteins that are associated with TRA 277 
(Supplementary Data 2) may be biomarkers of high prior gametocyte exposure rather than 278 
causally related to TRA. We thus curated this list of proteins by excluding genes with known 279 
or predicted intracellular products, while retaining genes based on evidence for a role in 280 
transmission reduction or gamete viability, or predicted compatibility with 281 
gametocyte/gamete surface expression. In addition to Pfs230 and Pfs48/45, 13 novel 282 
proteins possess sequence characteristics that are compatible with surface expression or 283 
have known roles in gamete viability (Table 3; Supplementary Data 5) and may thus form 284 
biologically plausible targets of transmission-inhibiting antibodies. mAbs specific to Pf11-1, 285 
one of the biomarkers with a role in gamete egress, were shown previously to reduce 286 
transmission to mosquitoes in membrane-feeding experiments [58]. 287 
Previous data show that the P. berghei homologue of another of our markers, 288 
PF3D7_1449000 (PfGEST), shows partial association with gamete surfaces and has a clear 289 
role in gamete egress [59]. We tested three monoclonal antibodies (mAb) against PfGEST in 290 
the SIFA and SMFA. SIFA with PfGEST mAbs showed no, or very limited surface reactivity, 291 
indicating that PfGEST is not retained on the gamete surface by 20 min after erythrocyte 292 
egress in P. falciparum (Supplementary Fig. 5B). Though two antibodies produced modest 293 
TRA in singlicate SMFA experiments at 10 μg/mL (generalised linear mixed model (GLMM): 294 
maximum 49.3% TRA, 95% CI: 31.0–62.8, p < 0.001), this was not replicable and showed 295 
no improvement with concentration (Supplementary Fig. 4). These data indicate that though 296 
naturally acquired PfGEST Ab appear to be biomarkers of TRA, there is no current evidence 297 
to support a mechanistic role in TRA.  298 
The 13 potentially surface expressed proteins were represented by 39 targets on the 299 
microarray, of which 16 were statistically significantly associated with TRA in the SMFA. 300 
Though antibody responses to most gametocyte proteins decrease with age, responses to 301 
these 16 targets shared a pattern more similar to Pfs48/45 and Pfs230; breadth of response 302 
to these targets increased with age (p = 0.007), whereas magnitude of response, though 303 
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highest in older individuals, showed no age-dependent association (Supplementary Fig. 6). 304 
Gametocyte-positive individuals recognising ≥ 4/16 of these targets (4 being the 75th 305 
percentile of breadth of response to these targets) showed lower infectiousness (LogR: OR 306 
0.36 (95% CI: 0.23–0.56), p < 0.001) and infection rates (OR 0.32 (95% CI: 0.16–0.62, p = 307 
0.001) in the DMFA (Fig. 3a, b). These patterns remained significant when Pfs48/45 or 308 
Pfs230 seropositive individuals were excluded (infectiousness: LogR, OR 0.34 (95% CI: 309 
0.20–0.58), p < 0.001; infection rate: OR 0.31 (95% CI: 0.15–0.64), p = 0.001). 310 
Discussion 311 
In this study, we assessed antibody-mediated transmission reducing activity (TRA) in 312 
individuals naturally exposed to P.falciparum and identified associated antibody responses. 313 
A minority of samples (3.3%) demonstrated strong and reproducible levels of TRA in 314 
controlled in vitro assessments with cultured P.falciparum gametocytes; high-level TRA was 315 
associated variably with antibody responses to gametocyte antigens Pfs48/45, Pfs230 and 316 
43 newly described proteins. These antibody responses were associated with reduced 317 
mosquito infection rates in feeding assays with local mosquito species on infected, 318 
gametocytaemic individuals. Although not all of the identified antibody responses will be 319 
causally involved in TRA, we provide the first direct evidence for independent roles of 320 
antibodies specific to Pfs48/45 and Pfs230 in naturally acquired TRA. The TRA of mAb 321 
specific to one of the novel TRA biomarkers, PfGEST, indicate that PfGEST antibodies 322 
elicited by P. falciparum exposure are likely to be non-functional biomarkers of TRA.  323 
The transmission of P. falciparum to mosquitoes is influenced by numerous factors, including 324 
gametocyte density [60], sex ratio [61] and human host factors that are currently poorly 325 
characterised. A direct effect of naturally acquired antibodies on transmission efficiency is 326 
suggested by the observation that mosquito infection rates generally increase in mosquito-327 
feeding experiments on naturally infected gametocyte carriers when autologous plasma is 328 
replaced by control serum [62]. Antibody responses to Pfs48/45 and Pfs230, established 329 
target antigens for transmission-blocking vaccines [15,36], are naturally acquired upon 330 
gametocyte exposure and have previously been statistically associated with TRA as 331 
measured in the SMFA [10,21–28]. The strength of these associations is variable and 332 
sometimes absent [29]; TRA is often observed in individuals without measurable α-Pfs48/45 333 
or α-Pfs230 antibodies [10,23,25,28,30,31]. We performed SMFA experiments on purified 334 
IgG samples from 648 malaria-exposed donors and confirm previous associations between 335 
TRA and α-Pfs48/45 (OR 4.4, 95% CI: 1.5–12.9) and α-Pfs230 antibodies (OR 7.9, 95% CI: 336 
2.8–22.8). Using a unique sample set with transmission data from DMFA from three endemic 337 
settings, we further provide the first evidence that α-Pfs48/45 and α-Pfs230 antibodies are 338 
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associated with reduced transmission efficiency during natural infections. Both the likelihood 339 
of infecting any mosquitoes and the proportion of infected mosquitoes were significantly 340 
lower for individuals with α-Pfs48/45 and α-Pfs230 antibodies. For the first time, we formally 341 
demonstrate that naturally acquired antibodies to these gametocyte antigens can 342 
independently inhibit mosquito infection after affinity purification.  343 
Despite the important role of antibodies to these two prefertilisation antigens, 45% of plasma 344 
donors with high-level TRA had no measurable α-Pfs48/45 or α-Pfs230 antibodies, and we 345 
observed significant levels of TRA after IgG from a selection of donors was depleted of α-346 
Pfs48/45 and α-Pfs230 antibodies. Our affinity purification experiments were based on the 347 
binding of antibodies to epitopes present in the Pfs48/45-10C and 230CMB vaccine 348 
constructs, as the proteins’ complex conformational structures so far preclude their 349 
production as full-length proteins. We thus captured the most potent transmission-reducing 350 
antibodies (Pfs48/45 epitopes 1–3 [21,22,36], Pfs230 epitopes within the C region [15]) but 351 
not necessarily all antibodies to these proteins. Monoclonal antibodies against epitope 5, 352 
which would not bind to the Pfs48/45-10C protein, have been associated with weak TR 353 
activity [63]. However, given their lower efficacy and the immunodominance of epitopes 1–3 354 
in naturally immune sera [21] it is highly unlikely that α-Pfs48/45 antibodies to epitopes other 355 
than epitopes 1–3 would have contributed considerably to TRA. This is also supported by 356 
the finding that antibodies to epitope 5 are only observed in the presence of antibodies to 357 
epitopes 1–321. Because all known α-Pfs230 antibodies are complement dependent [64,65], 358 
whereas TRA in the antibody-depleted fraction is complement independent, a role for 359 
residual α-Pfs230 antibodies (responsive to epitopes outside the aa. 444–730 region of 360 
Pfs230 represented by the 230CMB product) is similarly unlikely. Crucially, IgG depleted of 361 
antibodies to Pfs48/45 epitopes 1–3 recognised surface antigens of a knockout parasite line 362 
that fails to express Pfs48/45 and Pfs230, formally demonstrating recognition of other target 363 
antigens by immune sera. Our findings of TRA in the absence of measurable α-Pfs48/45 or 364 
α-Pfs230 antibodies, together with persisting recognition of gametes that do not express 365 
these two proteins, and functional TRA after depleting IgG of antibodies to these two targets, 366 
thus strongly suggest that responses to other antigens may contribute to naturally acquired 367 
TRA.  368 
Using a protein microarray, we aimed to identify whether responses to other gametocyte 369 
targets were associated with TRA. This array was enriched for putative gametocyte surface 370 
antigens but surface expression or gametocyte specificity were not prerequisites for 371 
inclusion on the array. Our aim was to determine an immune signature of TRA that could 372 
improve our understanding of transmission efficiency from natural infections. We therefore 373 
included markers of gametocyte exposure as well as general markers of recent malaria 374 
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infection. We observed that responses to 43 proteins were statistically significantly 375 
associated with high level antibody-mediated TRA. Responses to these antigens were 376 
strongly predictive of transmission efficiency from natural P.falciparum infections with diverse 377 
gametocyte strains and locally relevant mosquito species. Whilst further studies are needed 378 
to assess the generalisability of this signature of TRA across endemic settings, the strong 379 
association of our SMFA-based signature of TRA with reduced transmission potential during 380 
natural infections is very promising. Future studies should aim to assess the kinetics of 381 
antibody responses to these antigens and their association with TRA using longitudinal 382 
cohorts, with well-defined clinical, parasitological and infectivity data.  383 
The microarray proteins were produced in an Escherichia coli based in vitro transcription–384 
translation (IVTT) system. As conformation is not verified for all proteins, those requiring 385 
posttranslational modifications will likely not have been expressed in their native 386 
conformation. This was exemplified by Pfs48/45 that has a known complex structure [36,66] 387 
and showed minimal reactivity or discriminative power when printed on the array as an IVTT 388 
product (Supplementary Data 3). This apparent disadvantage of the IVTT system will 389 
plausibly have affected our results for other conformational proteins, so the list of proteins in 390 
Table 3 (and Supplementary Data 5) must be treated as a ‘rule in’ rather than ‘rule out’ 391 
selection for proteins associated with antibody-mediated TRA. Among the proteins we 392 
identified as having TRA-associated antibody responses, 13 novel proteins have sequence 393 
characteristics suggestive of surface expression and may be targets of TRA. Previous data 394 
indicate that two of the proteins found to be biomarkers of TRA in our analysis, PfGEST and 395 
Pf11-1, were previously shown to have important roles in gamete egress from the 396 
erythrocyte in mosquitoes [58,59]. Interestingly, Pf11-1 mAbs are able to reduce 397 
transmission, possibly by disabling full gamete egress [58]. Our SIFA data with humanised 398 
mAbs indicate that PfGEST has no clear surface expression in P. falciparum 20 min after 399 
activation, which may explain their lack of replicable TRA in mosquito-feeding assays 400 
compared to similar concentrations of α-Pfs230-specific mAb. As there is only a narrow 401 
window of opportunity for α-Pf11-1 and α-PfGEST antibody binding during gamete egress, 402 
activity against gamete surface proteins with roles in fertilization is a more biologically 403 
plausible mode of antibody mediated TRA. Future experiments may identify which of the 13 404 
other TRA-associated plausible antibody targets in Table 3 are expressed at the gamete 405 
surface. Our findings identify the further characterisation of functional and non-functional 406 
gametocyte antibody responses in individuals with naturally acquired TRA as a research 407 
priority. Although the prevalence of high-level TRA decreases with age, an opposite trend is 408 
observed for the magnitude and prevalence of antibodies to Pfs48/45 and Pfs230 and to 409 
newly identified gametocyte antigens, in spite of their overall association with TRA 410 
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(Supplementary Fig. 6). A better characterisation of these antibody responses in relation to 411 
functional activity is needed and may include a detailed assessment of antibody isotype, 412 
affinity and complement-binding activities. Regardless of their functionality, our data indicate 413 
that possession of antibody responses to a group of P. falciparum proteins increases the 414 
likelihood of antibody-mediated transmission inhibition. Combined with assessment of α-415 
Pfs48/45 and α-Pfs230, this signature of TR immunity may improve our understanding of 416 
natural malaria transmission dynamics. 417 
 418 
Methods 419 
Study participants. Serum was collected from individuals recruited to epidemiological 420 
studies in Burkina Faso, Cameroon and the Gambia (Table 1), as well as from Dutch 421 
migrants with a history of residence in P. falciparum malaria-endemic regions, who reported 422 
having been diagnosed with clinical malaria infection. Details of sample collection and 423 
recruitment criteria have been published for all samples from individuals living in endemic 424 
areas, but are provided here as a summary. Parasitological status was defined by 425 
microscopy acknowledging that this lacks the sensitivity to detect many low-density 426 
infections; i.e., microscopy negative samples were not treated as an unexposed control.  427 
Cameroon. Samples (n = 140) were collected between 2011 and 2015 from individuals aged 428 
5–16 years, during surveys at primary schools in the Mfou district, 30 km from Yaoundé. 429 
Data from these individuals have in part been presented previously [42,43], but the 430 
remainder were provided by Isabelle Morlais (IRD, Montpelier) without prior publication. 431 
Participants were primarily P. falciparum gametocyte carriers identified among asymptomatic 432 
children by microscopical screening. Gametocyte density (median (IQR) = 30 (16/80)/μL, 433 
among gametocyte positives) was calculated against 1000 leucocytes, assuming a density 434 
of 8000 leucocytes per μL.  435 
Gambia. Samples (n = 226) were collected from individuals resident in Farafenni and nearby 436 
villages, approximately 200 km east of Banjul, in 1992–1994 [24,44], 1998 and 1999 [45], 437 
2001 [46,47] and 2002 [48]. Individuals were aged 1–17 years at the point of sampling. 438 
Participants were enrolled if they were found to be asymptomatically infected with malaria 439 
parasites, based either on the observation of gametocytes [24,44], or asexual parasites [45–440 
48] by microscopy. Gametocyte density (median (IQR) = 63 (10/390)/μL, among gametocyte 441 
positives) was either calculated by examination of 100 high powered fields, assuming that 1 442 
gametocyte per field equated to 500/μL (threshold of 5 gametocytes/μL) as in Greenwood & 443 
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Armstrong 1991 [67], or by calculation against 1000 leucocytes, assuming a density of 8000 444 
leucocytes per μL.  445 
Burkina Faso. Samples were collected from residents in the villages of Laye and Dapélogo 446 
(n = 192), ~30 km northeast and north of Ouagadougo, in the Central Sudan savannah area 447 
[37,40,41], and from residents of Soumousso and Dande (n = 33), villages close to Bobo 448 
Dioulasso [38,39]. The age of study participants ranged from 1.8 to 74 years. Recruitment 449 
was either random [37,41], or based on the observation of gametocytes [38–40] or asexual 450 
parasites [40] by microscopy. Gametocyte density (median (IQR) = 64 (32/128)/μL, among 451 
gametocyte positives) was calculated against either 500 or 1000 leucocytes, assuming a 452 
density of 8000 leucocytes per μL.  453 
Netherlands. Dutch individuals were recruited by clinical staff at Radboud University Medical 454 
Centre in Nijmegen, the Netherlands, and had either recently returned ( < 6 months) from 455 
extended periods in endemic areas (n = 8) or had returned more than a year before 456 
sampling (n = 49). Age ranged from 26–84 years. Those who had returned more than a year 457 
before sampling had lived in areas with endemic P. falciparum transmission for longer than 458 
15 years and reported between 2 and >80 clinical malaria episodes during that time. For 459 
these individuals malaria infection history was only available through verbal testimony, 460 
whereas 3 out of 8 of the recently returned migrants had confirmed recent or current malaria 461 
infection. Samples were all collected between 1994 and 2014. As detailed previously, sera 462 
from some of these expatriates show strong and consistent TRA in the SMFA [68].  463 
All samples were collected after written informed consent was obtained from participants 464 
and/or their parent(s) or guardian(s). Ethical clearance was provided by the National Ethics 465 
Committee of Cameroon, the Gambian Government/Medical Research Council Joint Ethics 466 
Committee, the Ethical Review Committee of the Ministry of Health of Burkina Faso and the 467 
Centre MURAZ ethical review committees, the London School of Hygiene & Tropical 468 
Medicine ethics committee and by the Radboud University Medical Center ethical committee.  469 
Sample preparation. For SMFA, IgG was purified from all plasma samples using Protein G 470 
HP Spintrap (GE Healthcare, GE Uppsala, Sweden), and concentrated to the original serum 471 
volume using Vivaspin 20 centrifugal concentration columns (Sartorius AG, Goettingen, 472 
Germany) following the manufacturer’s instructions. Antibody purification was only attempted 473 
for samples with sufficient serum volume for duplicate SMFAs (180 μL). For the serological 474 
assays, an additional 30 μL of serum was retained if sample volume permitted. Because of 475 
the high serum volumes necessary for the antibody depletion/purification experiments, these 476 
were performed on only six samples with transmission-blocking antibodies. Three of these 477 
six were processed by protein microarray. IgG for depletion/purification was purified from 478 
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1mL of serum using protein G high performance affinity columns (HiTrap™ Protein G HP 1 479 
mL, GE Healthcare, Uppsala, Sweden), and then adjusted to the original serum volume for 480 
testing in the specific Pfs48/45 and Pfs230 affinity columns using Vivaspin 20 centrifugal 481 
concentration columns (Sartorius AG, Goettingen, Germany). Overall, 300 μL was 482 
immediately removed for SMFA and serological assays, leaving 700 μL of total IgG at 483 
physiological concentration for affinity column purification. Purification was repeated as 484 
required to allow for antibody eluate concentration.  485 
Direct membrane-feeding assay (DMFA). DMFA was performed during the original studies 486 
for 498/579 individuals from endemic areas, as described in the separate study protocols 487 
using identical glass mini-feeders [54] (Coelen Glastechniek, Weldaad, the Netherlands) and 488 
the same experimental protocol [69]. Of the 498 individuals with DMFA data, 494 had 489 
microscopy-based estimates of asexual and gametocyte density; only gametocyte positives 490 
(n = 366) were used in our DMFA analysis. All sites used colonies sourced from eggs caught 491 
in local water sources. Colonies were of A. gambiae s.s. (>90%) (The Gambia [24,44–48]), A. 492 
coluzzii (Cameroon [42,43] and Bobo Dioulasso in Burkina Faso [38,39]) or a comprised a 493 
mixture of A. coluzzii, A. gambiae s.s. and hybrid forms (other Burkina Faso sites [37,40,41]). 494 
Locally adapted mosquito colonies from all sites are available upon request. Data presented 495 
in the current manuscript are the proportion of infectious individuals and percent of 496 
mosquitoes infected with oocysts after feeding on whole blood [69]. 497 
Standard membrane-feeding assay (SMFA). Mosquitoes used for the assessment of 498 
antibody TRA in the SMFA were three to 5 day old female Anopheles stephensi (Sind-Kasur 499 
Nijmegen strain) [70], which were reared at 30 °C and 70–80% humidity while exposed to a 500 
12 h day/night cycle. Mature (stage IV-V) P. falciparum gametocytes (either NF54 [54], or 501 
transgenic NF54HT-GFP-Luc [71], depending on the preferred readout) were obtained from 502 
an automated tipper system (0.3–0.5% gametocytes, 2% haematocrit) and prepared with 503 
packed red blood cells as previously described [9,54]. Both gametocyte strains can be 504 
obtained from the MR4 Malaria Research and Reference Reagent Resource Center 505 
(https://www.beiresources.org/MR4Home.aspx). For the preparation of mosquito blood 506 
meals containing test antibodies, 90 μL of serum IgG was added to 90 μL of freeze-dried 507 
foetal calf sera (FCS) and diluted into 35 μL human serum containing active complement. 508 
This antibody/serum mix was added to the gametocyte/red blood cell mix to a final volume of 509 
270 μL, and kept at 37 °C until it was provided to mosquitoes in the membrane-feeding 510 
apparatus. Antibodies were therefore provided to mosquitoes at ~0.66* their physiological 511 
concentration (assuming a 1:1 plasma/cell ratio). Each SMFA run was performed to test up 512 
to 24 antibody samples simultaneously, including two control mosquito groups (against 513 
which the TRA of test samples was calculated). For control samples 90 μL of freeze-dried 514 
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FCS was dissolved in 90 μL milliQ and added to the same gametocyte/red blood cell mix 515 
(270 μL total volume) as was used for the other feeds the run.  516 
Prior to blood feeding, male mosquitoes were separated from females by aspiration. Unfed 517 
and partially fed female mosquitoes were removed from their resting containers after blood 518 
feeding. Fully engorged mosquitoes were maintained at 26 °C and 70–80% humidity. 519 
Mosquito infection status was determined differently for the NF54 and NF54HT-GFP-luc 520 
parasite strains. For experiments with the native NF54 strain, an average of 19.5 mosquitoes 521 
(range: 7–22) were dissected at day 7 post infection (PI). Midguts were stained in 1% 522 
mercurochrome and oocysts were counted by expert microscopists. For experiments with 523 
the transgenic NF54HT-GFP-luc strain, mosquitoes were killed on day 8 PI by freezing, and 524 
20 were homogenised for each experiment in two pools of 10. Mosquito homogenates were 525 
well mixed and three samples per pool were assayed for bioluminescence by lysis, and 526 
addition of luciferase assay substrate using a Luciferase assay kit (Luciferase assay system 527 
(E1501), Promega, USA), according to the manufacturer’s instructions and as previously 528 
described [9]. For experiments with the native NF54 strain, TRA was analysed as the 529 
percent difference in oocyst number between test and control mosquitoes.  530 
For experiments with the transgenic NF54HT-GFP-luc strain, TRA was calculated as the 531 
average percent difference in luminescence intensity for two pools of 10 mosquitoes 532 
between test and controls mosquitoes, as described9. TRA <0% was observed, but was 533 
generally within the normal range due to natural variation in oocyst intensity between 534 
mosquito groups. For individuals with TRA <0%, median TRA was -41.8% (IQR: −80.9–16.5). 535 
For experiments with replication (e.g. the affinity purification experiments) 95% CI around the 536 
TRA estimate were calculated from luminescence or microscopical readouts for multiple 537 
feeds using generalised linear mixed models (GLMMs) [72]. Choice of readout (and 538 
therefore of gametocyte strain) varied over the time that the SMFA’s were being performed, 539 
and makes no difference to the integrity or interpretation of TRA, only to its efficiency [9]. 540 
Overall, ≥90% reduction in oocyst/luminescence intensity in test mosquitoes relative to 541 
controls was classified as evidence of high-level TRA, which previous data indicate is highly 542 
replicable [68]. Samples from all individuals with ≥80% TRA were tested in duplicate to 543 
ensure robustness of the functional phenotype and the mean value of duplicate experiments 544 
was used to classify individuals as having high-level TRA (≥90% average reduction) or no 545 
evidence of TRA (<10% average reduction).  546 
Recombinant protein production for serological assays. Recombinant, correctly folded 547 
proteins were used for antibody depletion/purification experiments and for enzyme-linked 548 
immunosorbent assays (ELISA). For all assays assessing Pfs230-specific antibodies, we 549 
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used the transmission-blocking vaccine candidate 230CMB (developed and purified by 550 
Fraunhofer USA Center for Molecular Biotechnology), which corresponds to amino acids 551 
444–730 of the Pfs230 protein, and comprises the protein’s pro-domain and the first of 552 
fourteen cysteine motif domains [15]. For assays with Pfs48/45, two protein constructs were 553 
used. For antibody depletion/purification, we used the chimeric R0.10C protein [36], which 554 
comprises 10 cysteines spanning epitopes 1–3 of the Pfs48/45 C-terminal domain, fused to 555 
the GLURP R0 domain [36,40]. Antibodies specific to GLURP R0 have no effect on 556 
Plasmodium transmission to mosquitoes (Supplementary Table 2) [9]. For non-functional 557 
serologicalassays (ELISA, Microarray), the 10C protein was cleaved from the R0.10C as 558 
described previously [40].  559 
Monoclonal antibodies. SMFA data using mAb specific to GLURP R0, Pfs48/45 560 
(85RF45.1), Pfs230 (2A2) and PfGEST are presented in Supplementary Fig. 4 and 561 
Supplementary Table 2. Full details for GLURP R0 and Pfs48/45 (85RF45.1) mAb 562 
production and SMFA is provided in Stone et al. [9] Details of Pfs230 mAb production and 563 
SMFA are presented in Roeffen et al. 1995 [65]. PfGEST mAbs were produced by the 564 
Hypothesis-driven Pre-erythrocytic Antigen Target Identification Consortium (HPATIC). 565 
Briefly, HKL v2.0 KymiceTM containing human variable region genes (Kymab) were 566 
immunised with recombinant protein expressed in the wheat germ cell-free system (CellFree 567 
Sciences) adjuvanted with Montanide ISA 720. Non-antigen selected splenocytes were 568 
sorted into 96 well plates, one cell/well, to generate single-cell mRNA material (Atreca). 569 
Atreca’s Immune Repertoire Capture (IRCTM) provides Single-Cell mRNA Barcode-570 
Sequencing with high throughput and accuracy. This platform captured full-length sequences, 571 
enabling detection of somatic mutations across the entire antibody variable region. Natively 572 
paired heavy and light chain IgG variable regions were analysed, and constant region 573 
isotype assignments were made which were then produced via gene synthesis and 574 
recombinant expression as fully human antibodies (LakePharma). Three mAbs were tested 575 
in duplicate SMFA titration experiments. SMFA was conducted according to previously 576 
published protocols [9]. In all mAb-based SMFA, the endpoint was oocyst quantification by 577 
manual dissection. 578 
Pfs48/45 and Pfs230 antibody purification. To purify antibodies specific to the Pfs48/45 579 
and Pfs230 proteins from transmission-reducing sera, affinity columns were created by 580 
coupling 1 mg of R0.10C or 230CMB to N-hydroxysuccinimide (NHS)-activated high 581 
performance affinity chromatography columns (HiTrap™NHS-activated HP 1 mL, GE 582 
Healthcare, Uppsala, Sweden); coupling efficiency was >80%. 583 
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For the extraction of antibodies from human serum, antibodies were extracted first using the 584 
R0.10C column, and then using the 230CMB column, as follows. The R0.10C column was 585 
equilibrated with 2mL of binding buffer (PBS (1×) before 700 μL of total IgG (at physiological 586 
concentration, fraction 1 in Table 2) from transmission-blocking sera was added. The flow-587 
through was collected and the column washed with 12 mL of PBS. Overall, 5mL of elution 588 
buffer (0.15M NaCl,0.1M glycine/HCL, pH 2.5) was applied to the column for the collection 589 
for R0.10C-specific antibodies. After elution, the purification procedure was repeated using 590 
the flow-through from the first purification, and the antibody eluates from both runs were 591 
pooled. The final flow-through and combined antibody eluates (fraction 2a in Table 2) were 592 
concentrated to 700 μL using Vivaspin 20 centrifugal concentration columns (Sartorius AG, 593 
Goettingen, Germany). Overall, 300 μL of the flow-through was removed for SMFA (fraction 594 
3 in Table 2) and serological assays, and the remaining 400 μL was processed over the 595 
equilibrated 230CMB column as for the R0.10C column, except that the final flow-through’s 596 
(fraction 5 in Table 2) and eluates (fraction 4a in Table 2) were concentrated to 400 μL. 597 
Depletion of specific antibody in the flow-through’s of each column was confirmed with 598 
ELISA. Antibodies (from eluates or flow-troughs) were processed in the SMFA in two 599 
biological replicates, as for total IgG with >80% TRA in the larger SMFA screen. For three 600 
samples, larger starting volumes were used to allow antibody eluates to be concentrated 601 
nine times, to examine the effect of specific concentrated antibody on transmission-reducing 602 
activity (fractions 2b and 4b in Table 2). The possibility that TRA from the column fractions 603 
was due to cytokines or reactive ROx/RNOx species, which in circumstances of 604 
inflammatory crisis can inhibit parasite development in mosquitoes [73], was excluded both 605 
by our use of protein G binding columns for IgG purification for all samples, and our use of 606 
30 kDa filters for antibody concentration prior to mosquito-feeding.  607 
 608 
Surface immuno-fluorescence assays (SIFA). The Pfs48/45 KO NF54 P. falciparum line 609 
was produced and characterised by van Dijk et al3. and subsequently assessed by Eksi et al. 610 
[12] showed that Pfs230 is produced but not retained on surface of Pfs48/45 disruptant 611 
gametes. Wild-type (WT) and Pfs48/45 KO gametocytes were generated using standard 612 
protocols, as described above. Culture media Pfs48/45 KO line was supplemented with 2 613 
μM pyrimethamine. Briefly, gametocytes were allowed to activate at room temperature for 20 614 
min (for mAb SIFA) or 1 h (for human IgG SIFA) in the presence of foetal calf serum (FCS), 615 
and gametes were prepared for microscopy by washing with PBS supplemented with 0.5% 616 
FCS and 0.05% sodium azide. Antibodies were added to gamete preparations in the same 617 
PBS/FCS buffer; mAbs at 5 μg/mL; human IgG/sera at dilutions of 1:20. Secondary 618 
antibodies were Alexa Fluor TM 488 goat anti-human IgG (H+L), Alexa Fluor TM 488 619 
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chicken anti-mouse IgG (H+L), and Alexa Fluor TM 488 goat antirat IgG (H+L); all were 620 
added at dilutions of 1:200. All gamete preparations were incubated with secondary antibody 621 
at room temperature for 1 h.  622 
ELISA. Antibodies specific to the Pfs48/45-10 C and Pfs230 (230CMB) proteins were 623 
quantified in the ELISA exactly as described previously [40]. Optical density (OD) values 624 
were normalised between assay plates by adjustment relative to a consistent point in the 625 
linear portion of a standard curve of serially diluted highly reactive human sera. Cut-offs for 626 
positivity were determined from normalised OD values using maximum likelihood methods to 627 
define Gaussian populations of low and high responders as described previously [74]. For 628 
Dutch migrants who had returned from endemic areas ≥ 1 year before sampling, a 629 
seropositivity threshold was calculated as the mean+3 standard deviations of the averaged 630 
normalised OD values of eight naïve European control sera.  631 
Protein microarray. The selection of proteins to be cloned and printed on the arrays was 632 
made primarily based on observed expression by stage V P. falciparum gametocytes in a 633 
single recent proteomic analysis [52]. To ensure that the array included most potential 634 
antibody targets, we preferentially included proteins that had transmembrane domains, 635 
signal peptides or GPI anchors. To ensure that the majority of proteins that were highly 636 
abundant or ‘specific’ to mature gametocytes were included on the array, we used mass 637 
spectrometry data from the analysis of the stage V gametocyte proteome [52], alongside 638 
proteomic data from purified trophozoites [1] and schizonts (Supplementary Data 6, PRIDE 639 
accession number: PXD008250) generated in the same laboratory. Gametocyte and asexual 640 
stage specific expression data sets were generated in relative expression values to compare 641 
protein abundances (label-free quantitative (LFQ) values) between the stages, which are 642 
presented in Supplementary Data 1 as a fold-change value.  643 
We chose to also include proteins that were potential markers of gametogenesis identified 644 
by Silvestrini et al [1]. These proteins we identified as being expressed primarily by early 645 
gametocytes, or shared between stages (proteins for 32/59 were present in the stage V 646 
database), but some were more abundant in mature gametocytes or other parasite life 647 
stages (Supplementary Data 1). In addition to these markers, we included four putative 648 
markers of asexual parasite exposure: PF3D7_1036000 (Merozoite surface protein 11 649 
(MSP11)), PF3D7_0711700 (erythrocyte membrane protein 1, PfEMP1 (VAR)), 650 
PF3D7_0731600 (acyl-CoA synthetase (ACS5)), and PF3D7_0423700 (early-transcribed 651 
membrane protein 4 (ETRAMP4)), based on work by Helb et al [51].  652 
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Details of the 315 proteins included on the array are given in Supplementary Data 1. 653 
Proteins with reference sequences longer than 1000 amino acids were split into multiple 654 
fragments (overlaps of at least 17 a.a) for cloning, in vitro protein expression and printing. 655 
Because the basic criteria for the selection of proteins for microarray construction was based 656 
on data generated from a single laboratory, we cross-referenced our protein list against a 657 
cross-study analysis of gametocyte specificity [53]. In short, the specificity of any protein for 658 
the gametocyte stage was scored by determining how often it had been detected across 11 659 
proteomic analyses (listed in Supplementary Data 1: 3 of gametocytes only, 3 of asexual 660 
stages only, and 5 of both asexuals and gametocytes). Proteins were binned from low to 661 
high abundance and weighted according to the retrieval rates of proteins in two curated lists 662 
of ‘gold standard’ gametocyte and asexual genes, consisting of genes that are known to be 663 
specific for either asexual stages (n = 45) or gametocytes (n = 41). High expression of 664 
gametocyte gold standard proteins with concurrent absence of nongametocyte gold standard 665 
proteins resulted in a high gametocyte score, calculated from the fraction of retrieved 666 
gametocyte genes over retrieved non-gametocyte genes. All scores were log-transformed 667 
and summed over all data sets. Gametocyte scores were categorised using the scores’ 668 
distribution of the gametocyte gold standard as follows: scores above the first quartile (9.69) 669 
were considered gametocyte-specific. Proteins scoring at least as high as the lowest scoring 670 
gametocyte gold standard representative (-2.46) were considered as enriched in 671 
gametocytes. Proteins with lower scores are not specific to a certain life stage and have 672 
some evidence for expression in gametocytes. All proteins scoring lower than the median of 673 
the asexual gold standard (-18.98) were considered asexual specific. This analysis  674 
confirmed that 228 of the 315 proteins had consensus evidence for enrichment in 675 
gametocytes (scores >−2.46), whereas 284/315 had conservative evidence for expression in 676 
gametocytes (peptides present in at least one gametocyte proteomic database, score >−10). 677 
312/315 were present in at least one gametocyte proteomic database, giving rise to a 678 
score >−18.93. Scores for all proteins on the array are included in Supplementary Data 1. To 679 
avoid further curation and potential bias, no proteins were excluded prior to analysis.  680 
Proteins were expressed using an in vitro transcription and translation (IVTT) system, the 681 
Escherichia coli cell-free Rapid Translation System (RTS) kit (5 Prime, Gaithersburg, MD, 682 
USA). A library of partial or complete CDSs cloned into a T7 expression vector pXI has been 683 
established at Antigen Discovery, Inc. (ADI, Irvine, CA, USA). This library was created 684 
through an in vivo recombination cloning process with PCR-amplified CDSs, and a 685 
complementary linearised expressed vector transformed into chemically competent E. coli 686 
was amplified by PCR and cloned into pXI vector using a high-throughput PCR 687 
recombination cloning method described elsewhere [50]. Each expressed protein includes a 688 
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5′ polyhistidine (HIS) epitope and 3′ hemagglutinin (HA) epitope. After expressing the 689 
proteins according to manufacturer instructions, translated proteins were printed onto 690 
nitrocellulose-coated glass AVID slides (Grace Bio-Labs, Inc., Bend, OR, USA) using an 691 
Omni Grid Accent robotic microarray printer (Digilabs, Inc., Marlborough, MA, USA). Each 692 
slide contained eight nitrocellulose ‘pads’ on which the full array was printed, allowing eight 693 
samples to be probed per slide. Microarray chip printing and protein expression were quality 694 
checked by probing random slides with anti-HIS and anti-HA monoclonal antibodies with 695 
fluorescent labelling. Each chip contained 28 IVTT negative control targets (for data 696 
normalisation), and 48 IgG positive control targets (for quality control).  697 
For analysis of antibody reactivity on the protein microarray, serum samples were diluted 698 
1:200 in a 3 mg mL−1 E. coli lysate solution in protein arraying buffer (Maine Manufacturing, 699 
Sanford, ME, USA) and incubated at room temperature for 30 min. Chips were rehydrated in 700 
blocking buffer for 30 min. Blocking buffer was removed, and chips were probed with pre-701 
incubated serum samples using sealed, fitted slide chambers to ensure no cross-702 
contamination of sample between pads. Chips were incubated overnight at 4°C with 703 
agitation. Chips were washed five times with TBS-0.05% Tween 20, followed by incubation 704 
with biotin-conjugated goat anti-human IgG (Jackson ImmunoResearch, West Grove, PA, 705 
USA) diluted 1:200 in blocking buffer at room temperature. Chips were washed three times 706 
with TBS-0.05% Tween 20, followed by incubation with streptavidin-conjugated SureLight P-707 
3 (Columbia Biosciences, Frederick, MD, USA) at room temperature protected from light. 708 
Chips were washed three times with TBS-0.05% Tween 20, three times with TBS, and once 709 
with water. Chips were air dried by centrifugation at 1000×g for 4 min and scanned on a 710 
GenePix 4300A High-Resolution Microarray Scanner (Molecular Devices, Sunnyvale, CA, 711 
USA). Target and background intensities were measured using an annotated grid file (.GAL).  712 
Raw microarray protein target and local background fluorescence intensities, target 713 
annotations and sample phenotypes were imported and merged in R (Foundation for 714 
Statistical Computing, Vienna, Austria), where all subsequent procedures were performed. 715 
Foreground target intensities were corrected for local background using the 716 
backgroundCorrect function of the limma package [75]. Next, all corrected values were 717 
transformed using the base 2 logarithm. The data set was normalised to remove systematic 718 
effects by subtracting the median signal intensity of the IVTT controls for each sample. As 719 
the IVTT control targets carry the chip, sample and batch-level systematic effects, but also 720 
antibody background reactivity to the IVTT system, this procedure normalises the data and 721 
provides a relative measure of the specific antibody binding to the non-specific antibody 722 
binding to the IVTT controls (a.k.a. background). With the normalised data, a value of 0.0 723 
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means that the intensity is no different than the background, and a value of 1.0 indicates a 724 
doubling with respect to background. 725 
Data analysis. Quality control plots were made after each treatment of the microarray data, 726 
which included boxplots and density plots of probe intensity by study sample and probe type. 727 
Recombinant Pfs230 CMB was printed on the array for comparison to ELISA with the same 728 
protein, yielding a correlation co-efficient (Spearman’s rank) of 0.44 (p < 0.001). A universal 729 
seropositivity threshold for reactivity to array proteins was established as the IVTT 730 
background plus 3 standard deviations, which equated to a log2-transformed signal intensity 731 
threshold of 0.92 (reactivity was therefore defined as approximately twice that of the 732 
background). Because high-level transmission-reducing activity was uncommon in our 733 
sample set (22/649 samples had TRA ≥90%), antigens were defined as ‘reactive’ if they 734 
elicited seropositive responses in at least 1% of the study population (≥7 subjects), and 735 
unreactive antigens were included in all analyses. The universal cut-off was used only for 736 
defining proteins as reactive or unreactive, and for depicting antibody breadth for all 737 
microarray proteins. 738 
Statistical analysis was conducted using R (Foundation for Statistical Computing, Vienna, 739 
Austria) or STATA 12 (StataCorp., TX, USA). The magnitude of antibody reactivity to each 740 
antigen on the microarray by individuals in different groups was tested by empirical Bayes-741 
moderated t-tests [76], and by logistic regression after data binarisation using protein-742 
specific cut-offs; cut-offs were generated using maximum liklihoods methods (which 743 
determines the junction between two Gaussian signal distributions for each protein that 744 
proteins cut-off point for positivity) [74]. For the latter, proteins were dis-included from the 745 
analyses if the mixture models failed to stably converge, or had to restart more than once. In 746 
both the Bayes and logistic models, p-values were adjusted to control the false discovery 747 
rate below 5% using the Benjamini–Hochberg (BH) method [57], and a finding was 748 
considered significant for FDR controlled p-values (q-values) <0.05. 749 
For analysis of TRA on a continuous scale, TRA was used as the log-transformed relative 750 
intensity, to normalise the data and avoid compression at 0%. For clarity, figures presenting 751 
TRA on a continuous scale present the linear TRA with a base of 0%. Linear models with 752 
adjustment for gametocyte density (determined by microscopy, and given as 753 
gametocytes/μL) were used to test for differences in continuous variables between groups. 754 
Logistic models adjusted for gametocyte density were used to test for the association of 755 
binary variables between groups, presenting odd-ratios and 95% CI. Differences in the 756 
magnitude of response to all proteins by groups of individuals (in contrast to the Bayes 757 
analysis, which compares responses to individual proteins by different groups of individuals) 758 
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were assessed with t-tests or ANOVA. Differences in mosquito infection prevalence in the 759 
DMFA were analysed with logistic models adjusted for gametocyte density, while differences 760 
in mosquito oocyst prevalence were assessed with logistic models, adjusted for gametocyte 761 
density and with host (individual the mosquitoes were feeding upon) as a random effect. All 762 
boxplots are standard Tukey’s whisker and boxplots, with Tukey’s method for outlier 763 
determination. All DMFA-based analysis was performed on gametocyte-positive individuals 764 
only. Protein-domain predictions for proteins with TRA-associated responses were made 765 
using Interpro [77] or HhPred protein-domain prediction [78]. 766 
Data availability. The novel P. falciparum Schizont mass spectrometry proteomics data 767 
have been deposited to the ProteomeXchange Consortium 768 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository [79] with the 769 
data set identifier PXD008250. The authors declare that all other data supporting the 770 
findings of this study are available within the article and its Supplementary Information, have 771 
been deposited in the DRYAD data depository (https://doi.org/10.5061/dryad.8bp05), or are 772 
available from the authors upon request. 773 
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790 
Figure 1. Antibody responses to Pfs48/45, Pfs230 and to the microarray proteins with age. 791 
Antibody responses to correctly folded, recombinant Pfs48/45- 10C and Pfs230 (230CMB) 792 
were measured using ELISA, with antibody intensity given as the ELISA optical density (OD) 793 
values (450 nm). Antibody responses to microarray proteins are given as the log2-794 
transformed signal intensity (SI) minus the vehicle SI, which equates to the log2-fold change 795 
over this background. All graphs show only individuals from endemic areas (Dutch migrants 796 
excluded). Sample size: 0–5 = 131, 5–15 = 366, 15+ = 71. a, c Bars show the 797 
seroprevalence of α-Pfs48/45 and α-Pfs230 antibodies with age, with Clopper–Pearson 798 
confidence intervals. b, d Boxplots showing α-Pfs48/45 and α-Pfs230 antibody intensity with 799 
age. e Boxplots showing responses to the microarray protein targets (n = 528). Antibody 800 
breadth is the number of proteins reactive above background in each individual, within the 801 
given groups. f Magnitude of antibody response to microarray protein targets. Each dot 802 
represents the average SI of response to each protein target by all individuals within given 803 
groups. p-values for prevalence data are from likelihood ratio test for differences in 804 
seroprevalence between all age groups, derived from logistic regression and adjusted for 805 
gametocyte density. p-values for intensity data and response breadth are from an F-test for 806 
differences in OD/SI between all age groups, derived from linear regression and adjusted for 807 
gametocyte density or from ANOVA (for magnitude only). For all boxplots, outliers are shown 808 
in black, whereas all data points are shown in grey as a bee-swarm. 809 
 810 
 811 
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 812 
Figure. 2 Transmission-reducing activity (TRA) and antibody responses to Pfs48/45, Pfs230 813 
and microarray proteins. TRA was categorised as described, to compare responses between 814 
gametocyte-positive individuals with <10% TRA, and individuals with >90% TRA. Antibody 815 
responses to correctly folded, recombinant Pfs48/45-10C and Pfs230 (230CMB) were 816 
measured using ELISA, with antibody intensity given as the ELISA optical density (OD) 817 
values (450 nm). Antibody responses to microarray proteins are given as the log2-818 
transformed signal intensity (SI) minus the vehicle SI, which equates to the log2-fold change 819 
over this background. a, b Boxplots of α-Pfs48/45 and α-Pfs230 antibody intensity with TRA. 820 
c Responses to the microarray protein targets (n = 528). Antibody breadth is the number of 821 
proteins reactive above background in each individual, within the given groups. d Magnitude 822 
of antibody response to microarray protein targets. Each dot represents the average SI of 823 
response to each protein target by all individuals within given groups. p-values for intensity 824 
data and response breadth are from an F-test for differences in OD/SI between all age 825 
groups, derived from linear regression, and adjusted for gametocyte density or from students 826 
t-test (for magnitude only). For all boxplots, outliers are shown in black, whereas all data 827 
points are shown in grey as a bee-swarm. e Volcano plot showing the log2-fold change of 828 
the mean signal intensity for TRA as defined above. The p-value shown by the dotted line is 829 
unadjusted for false discovery. Black-circled data points are those that remain significant 830 
after p-values have been adjusted to control the rate of false discovery below 5%, using the 831 
Benjamini–Hochberg method. 832 
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 834 
Figure. 3 Seroprevalence to Pfs48/45, Pfs230, and novel TRA-associated microarray 835 
proteins, and infectiousness in the direct membrane-feeding assay (DMFA). Individuals with 836 
DMFA data were categorised according to their possession of antibodies specific to: 837 
Pfs48/45 (positive (+)/negative (−)); Pfs230 (positive (+)/negative (−)); ≥14 of the 61 novel 838 
microarray proteins with TRA-associated antibody responses (14 being the 75th percentile of 839 
the breadth of response to these microarray targets among the entire sample set); ≥4 of the 840 
16 novel microarray proteins with TRA-associated antibody responses that are also plausible 841 
targets of antibodies with TRA (4 being the 75th percentile of the breadth of response to 842 
these microarray targets among the entire sample set). a Bars show the proportion of 843 
infectious individuals among seropositive/seronegative gametocytaemic individuals with 844 
DMFA data, with Clopper–Pearson confidence intervals. n/N = number of individuals 845 
seropositive/total number of individuals with DMFA data. P-values are from logistic 846 
regression, with adjustment for gametocyte density. b Boxplots show the percentage of 847 
mosquitoes that became infected after feeding. n/N = the number of mosquitoes feeding on 848 
seropositive individuals/the total number of mosquitoes feeding on individuals with DMFA 849 
data. p-values are from logistic models, adjusted for gametocyte density and with host 850 
(individual the mosquitoes were feeding upon) as a random effect. For all boxplots, outliers 851 
are shown as hollow black circles, whereas all data points are shown as solid coloured 852 
circles. 853 
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 854 
Figure. 4 Gamete surface immuno-fluorescence assay (SIFA) using wild-type and Pfs48/45 855 
knockout (KO) NF54 gametes, with Pfs48/45 mAb, Pfs230 mAb, and IgG from a malaria-856 
exposed serum donor. Donor IgG is from donor A in Table 2, and was performed using total 857 
IgG, and total IgG depleted of α-Pfs48/45-10c and α-Pfs230 (230CMB) IgG. Δ Pfs48/45 = 858 
Pfs48/45 KO3. BF Bright-field, FITC fluorescein isothiocyanate. Anti-Pfs48/45 is mAb 45.1, 859 
and anti-Pfs230 is mAb 2A2, as described in the methods. Scale bar is 20 μm. 860 
 861 
 862 
 863 
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69. Ouédraogo, A. L. et al. A protocol for membrane feeding assays to determine the 1040 
infectiousness of P. falciparum naturally infected individuals to Anopheles gambiae. MWJ 4, 1041 
16 (2013). 1042 
70. Feldmann, A. M. & Ponnudurai, T. Selection of Anopheles stephensi for refractoriness 1043 
and susceptibility to Plasmodium falciparum. Med. Vet. Entomol. 3, 41–52 (1989). 1044 
71. Vaughan, A. M. et al. A transgenic Plasmodium falciparum NF54 strain that expresses 1045 
GFP–luciferase throughout the parasite life cycle. Mol. Biochem.Parasitol. 186, 143–147 1046 
(2012). 1047 
72. Churcher, T. S. et al. Measuring the blockade of malaria transmission—an analysis of 1048 
the standard membrane feeding assay. Int. J. Parasitol. 42, 1037–1044 (2012). 1049 
34 
 
73. Naotunne, T. S., Karunaweera, N. D., Mendis, K. N. & Carter, R. Cytokinemediated 1050 
inactivation of malarial gametocytes is dependent on the presence of white blood cells and 1051 
involves reactive nitrogen intermediates. Immunology 78, 555–562 (1993). 1052 
74. Cook, J. et al. Serological markers suggest heterogeneity of effectiveness of malaria 1053 
control interventions on Bioko Island, Equatorial Guinea. PLoS ONE 6, e25137 (2011). 1054 
75. Ritchie, M. E. et al. limma powers differential expression analyses for RNA sequencing 1055 
and microarray studies. Nucleic Acids Res. 43, e47 (2015). 1056 
76. Smyth, G. K. Linear models and empirical bayes methods for assessing differential 1057 
expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, 3 (2004). 1058 
77. Finn, R. D. et al. InterPro in 2017—beyond protein family and domain annotations. 1059 
Nucleic Acids Res. 45, D190–D19 (2017). 1060 
78. Alva, V., Nam, S.-Z., Söding, J. & Lupas, A. N. The MPI bioinformatics Toolkit as an 1061 
integrative platform for advanced protein sequence and structure analysis. Nucleic Acids 1062 
Res. 44, W410–W415 (2016). 1063 
79. Vizcaino, J. A. et al. The PRoteomics IDEntifications (PRIDE) database and associated 1064 
tools: status in 2013. Nucleic Acids Res. 41, D1063–D1069 (2013). 1065 
Supplementary Information 
 
Supplementary Figure 1. Antibody responses to the gametocyte protein microarray, with age data for Burkina 
Faso only. Responses by age are for individuals from Burkina Faso only, which was the only endemic country with 
substantial numbers of recruits from all age groups. Antibody breadth is the number of proteins reactive above 
background in each individual. Antibody magnitude is the log2-transformed average signal intensity (SI) for each 
microarray target, minus the vehicle SI. This equates to the log2-fold change over background. Responses are shown 
to each protein target by all individuals within given groups. For all box-plots, outliers are shown in black while all 
data points are shown in grey as a bee-swarm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2. Gametocyte density and transmission reducing activity.   Gametocyte density and TRA over age (A & B) are for individual’s living in endemic areas 
only. Gametocyte density is shown to 1000 gametocytes/µL in A and D. Values above this limit are excluded from the plots (points missing: 0-5=7, 5-15=12, 15+=0), but not 
the summary statistics for the box-plots (median, IQR). TRA on a continuous scale (B & C) is presented as absolute TRA for clarity, but the p values are from simple linear 
regression using log relative infectivity (log[oocysts in treatment mosquitoes/oocysts in control mosquitoes]), to normalise the data and avoid compression at zero. All plots 
and statistical analysis with age or gametocyte density include only individuals from endemic areas. Grouped TRA (D) is presented for individuals with antibodies causing 
TRA (TRA) ≥90% vs gametocyte positive individuals with antibodies causing TRA <10%, as presented elsewhere. For all box-plots, outliers are shown in black while all data 
points are shown in grey as a bee-swarm. 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3. Mosquito infection prevalence decreases with breadth of response to novel TRA associated protein across all gametocyte densities. Breadth of 
response to the 62 novel TRA associated protein targets from the array analysis were binned into quartiles among the population with DMFA data (n=366). Box plots show 
the median, 25th, 75th 5th and 95th percentiles of mosquito infection prevalence. For all box-plots, outliers are shown as hollow circles. 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4. TRA of mAbs against Pfs48/45, Pfs230, and novel biomarker PfGEST. For Pfs230 and PfGEST mAB, TRA was calculated against isotypic negative 
control mAb (α-CSP). Pfs48/45 TRA was calculated using human serum as negative control. Details for Pfs48/45 (85RF45.1) mAb production and SMFA is provided in Stone 
et al. 2014 1. Details of Pfs230 mAb production and SMFA are presented in Roeffen et al. 1995 2. PfGEST mAb were produced by the Hypothesis-driven Pre-erythrocytic 
Antigen Target Identification Consortium (HPATIC) and provided by PATH. SMFA was conducted according to previously published protocols 1. In all mAb based SMFA, the 
endpoint was oocyst quantification by manual dissection. Between 20 and 60 mosquitoes were dissected in each experiment. P-values are from a generalised linear mixed 
model (GLMM), as described previously 3. 
 
 
 
 
 
Supplementary Figure 5. Gamete surface immuno-fluorescence assay (SIFA) using wild-type and Pfs48-45 KO NF54 
gametes, with PfGEST mAb and IgG/plasma from a malaria exposed serum donor. Donors B and E and naïve donor 
plasma are described in table 2. SIFA was performed with human antibody sources from whole plasma or total IgG 
depleted of α-Pfs48/45-10c and α-Pfs230CMB Ab. Δ Pfs48/45 = Pfs48/45 KO 4. BF = Bright-field, FITC = fluorescein 
isothiocyanate. GEST mAbs were a mixture of 5µg/mL of all three GEST mAbs described in the methods. Scale bar is 
20µm. A. Donor sera, B. mAb, with serum for comparison. 
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Supplementary Figure 6. Figure 1. Antibody responses to Pfs48/45-10C, Pfs230 and to the microarray proteins 
with age, with microarray targets that are plausible antibody targets indicated. Antibody responses to 
conformational, recombinant Pfs48/45 and Pfs230 were measured using ELISA, with antibody intensity given as the 
ELISA optical density (OD) values (450nm), which is normalised between assay plates by adjustment relative to a 
consistent point in the linear portion of a standard curve of serially diluted highly reactive human sera. Antibody 
responses to microarray proteins are given as the log2-transformed signal intensity (SI) minus the vehicle SI, which 
equates to the log2-fold change over this background. All graphs show only individuals from endemic areas (Dutch 
migrants excluded). Sample size: 0-5 = 131, 5-15 = 366, 15+ = 71. A & C: Bars show the seroprevalence of α-Pfs48/45-
10C and α-Pfs230 antibodies with age, with Clopper-Pearson confidence intervals. B & D: Box plots showing α-
Pfs48/45-10C and α-Pfs230 antibody intensity with age. E: Box-plots showing responses to the microarray proteins 
(n=528), and the targets which were identified as having characteristics which make surface expression or 
involvement in gamete viability possible (n=16). As indicated in the text, these 16 targets represent fragments of 13 
unique proteins. Antibody breadth is the number of proteins reactive above background in each individual, within 
the given groups. F: Magnitude of antibody response to microarray proteins and plausible Ab targets. Each spot 
represents the average SI of response to each protein target by all individuals within given groups. P-values for 
prevalence data are from likelihood ratio test for differences in seroprevalence between all age groups, derived from 
logistic regression, and adjusted for gametocyte density. P values for intensity data and response breadth are from 
an F test for differences in OD/SI between all age groups, derived from linear regression, and adjusted for 
gametocyte density, or from students t-test (for magnitude only). For all box-plots, outliers are shown with larger 
black/red dots while all data points are shown in grey/red as a bee-swarm of small dots. 
 
 
Supplementary Tables 
Supplementary Table 1. Transmission-reducing activity and association with Pfs48/45 and Pfs230 antibody responses 
SMFA selection Samples 
Pfs230 (230CMB) Pfs48/45 (Pfs48/45-10C) Either/both of Pfs230 and Pfs48/45 
% (n/N) 
OR 
(TRA >90%) 
95% CI p-value % (n/N) 
OR 
(TRA>90%) 
95% CI p-value % (n/N) 
OR 
(TRA>90%) 
95% CI p-value 
Total TRA (all) 648 16.2% (105/648) - - - 14.4% (93/648) - - - 21.8% (141/648) - - - 
Blockers TRA ≥90% 22 50.0% (11/22) - - - 40.9% (9/22) - - - 54.5% (12/22) - - - 
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s TRA <90% 626 15.0% (94/626) 5.8 2.2-15.8 <0.001 13.4% (84/626) 4.0 1.4-11.3 0.009 20.6% (129/626) 5.1 1.9-14.0 0.001 
TRA <10% 405 15.6% (63/405) 5.5 2.0-15.3 0.001 14.6% (59/405) 3.7 1.3-10.5 0.015 22.0% (89/405) 4.7 1.7-13.0 0.003 
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TRA <90% 406 12.1% (49/406) 7.3 2.6-20.3 <0.001 11.1% (45/406) 4.7 1.6-13.6 0.004 17.2% (70/406) 6.2 2.2-17.0 <0.001 
TRA <10% 254 10.6% (27/254) 8.2 2.9-23.7 <0.001 11.4% (29/254) 4.5 1.5-13.2 0.006 16.9% (43/254) 6.2 2.19-17.45 0.001 
 
% (n/N) Seroprevalence of antibody responses to Pfs230, Pfs48/45, or either protein. n = seropositive individuals, N=total population size 
TRA % Transmission-reducing activity of purified IgG in the standard membrane-feeding assay (SMFA), relative to control mosquitoes fed the same gametocyte batch without test 
antibodies. TRA is the mean of two independent SMFA runs for all samples.  
Samples  Total number of samples with TRA assessed in the SMFA 
n/N  Number of samples seropositive in ELISA/Number of samples assessed in the ELISA 
OR (TRA ≥90%) Odds ratio of association of seropositivity and TRA, where the presence of TRA is defined as TRA ≥90%, and the absence of TRA is defined by the comparator groups TRA 
<90%, and <10%. Logistic models are adjusted for gametocyte density. 
95% CI  95% confidence intervals of the OR 
p-value  P-value from the logistic model used to generate the OR 
 
 
 
 
 
Supplementary Table 2. The TRA of GLURP-R0 compared to dilutions of mAb specific to Pfs48/45 epitope 1 (85RF45.1) and control human serum in the SMFA. Full details 
of these SMFA experiments are in Stone et al. 20145.  
 
Treatment 
SMFA 1 
 
SMFA 2 
 
SMFA 3 
 
Mean 
oocysts 
TRA % 
Mean 
oocysts 
TRA % 
Mean 
oocysts 
TRA % 
Control (human serum) 6.8 - 13.3 - 17.9 - 
85RF45.1 mAb (0.15µg/ml) 6.3 7.2 11.2 15.8 30.7 -71.4 
85RF45.1 mAb  (0.3µg/ml) 2.9 57.0 13.6 -2.5 16.1 10.2 
85RF45.1 mAb (0.6µg/ml) 1.4 79.8 7.5 43.7 9.2 48.7 
85RF45.1 mAb (1.25µg/ml) 0.1 98.0 1.2 90.7 1.9 89.4 
85RF45.1 mAb (2.5µg/ml) 0.1 99.0 0.4 96.7 0.3 98.5 
GLURP mAb (2.5µg/ml) 6.9 -2.2 14.1 -6.0 12.1 32.5 
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